Brokerages Set $5.33 Price Target for Medgenics Inc (GNMX)

Medgenics Inc (NASDAQ:GNMX) has been given a consensus broker rating score of 2.50 (Hold) from the two brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and one has assigned a buy recommendation to the company.

Brokers have set a 1-year consensus price objective of $5.33 for the company and are forecasting that the company will post ($0.15) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Medgenics an industry rank of 195 out of 265 based on the ratings given to its competitors.

How to Become a New Pot Stock Millionaire

Shares of Medgenics (GNMX) traded down $0.04 during trading hours on Friday, hitting $2.03. The stock had a trading volume of 46,217 shares, compared to its average volume of 233,114. The firm has a market cap of $121.05, a P/E ratio of -2.33 and a beta of 1.06. Medgenics has a 12 month low of $0.98 and a 12 month high of $5.60.

An institutional investor recently raised its position in Medgenics stock. Wells Fargo & Company MN increased its holdings in Medgenics Inc (NASDAQ:GNMX) by 433.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 130,662 shares of the biotechnology company’s stock after acquiring an additional 106,178 shares during the period. Wells Fargo & Company MN owned about 0.35% of Medgenics worth $165,000 at the end of the most recent quarter. 20.51% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at

Medgenics Company Profile

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn’s disease.

Get a free copy of the Zacks research report on Medgenics (GNMX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Medgenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medgenics and related companies with's FREE daily email newsletter.

Leave a Reply